Haemonetics has patented a method for preparing quality control formulations for testing viscoelastic analysis reagents without using human donor-derived blood components. The method involves determining target concentrations of bovine citrated plasma, human tissue factor, and heparin, and combining them to create the formulation. GlobalData’s report on Haemonetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Haemonetics Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Haemonetics, Glucose monitoring wearbles was a key innovation area identified from patents. Haemonetics's grant share as of February 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.

Quality control formulations for viscoelastic analysis reagents

Source: United States Patent and Trademark Office (USPTO). Credit: Haemonetics Corp

A recently granted patent (Publication Number: US11906532B2) outlines a method for preparing a formulation to test the efficacy of viscoelastic analysis reagents. The formulation includes specific concentrations of bovine citrated plasma, human tissue factor, and heparin. The method involves determining the target concentrations of each component by preparing dilutions, measuring viscoelastic characteristics, and extrapolating the target values through linear regression. The formulation is then prepared by combining the components at the specified concentrations.

Furthermore, the patent details variations in the method, such as different concentrations in the dilutions for each component and the simultaneous performance of steps to streamline the process. The formulation, as described in the patent, consists of specific ranges of bovine citrated plasma, human tissue factor, and heparin, along with additional criteria like pH, total protein content, and the inclusion of a stabilizing agent. The method aims to provide a standardized and reproducible formulation for testing viscoelastic analysis reagents, ensuring accurate and reliable results in assessing their efficacy.

To know more about GlobalData’s detailed insights on Haemonetics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.